Study: Biosimilar vs Originator Spending on Comparative Efficacy Trials

March 04, 2021

Investigators evaluated trial spending and reasons for biologics license application failures.

Biosimilars Rheumatology Roundup
Biosimilars Quiz: Which years have brought AbbVie the highest revenues for adalimumab?
News Briefs: Samsung Bioepis, Cipla, Biocon Report Progress
NCCN Issues Guidelines for Biosimilar Use